通讯作者: 王卿炜, wangqingwei@fjsjjsyy.cn

DOI：10.12201/bmr.202603.00103

Clinical Efficacy and Quality of Life Evaluation of Integrated Traditional Chinese-Western Medicine Staging Therapy for Granulomatous Lobular Mastitis

• 摘要：目的：探讨中西医结合分期论治策略在肉芽肿性小叶性乳腺炎（granulomatous lobular mastitis，GLM）不同阶段的临床疗效及对患者生活质量的改善作用。方法：回顾分析2022年6月至2024年6月收治的78例GLM患者，分为中西医结合组（40例）与西医组（38例）。中西医结合组根据分型分期采用中药联合小剂量激素或手术治疗，西医组以激素及手术治疗为主。采用临床疗效指标（包括总有效率、复发率、激素使用时长及术后乳房外形满意度）并结合健康调查量表-36（36-item Short Form Health Survey，SF-36）总分来综合评估疗效。结果：两组患者半年总有效率、半年总治愈率差异均无统计学意义（P＞0.05）。中西医结合组1年总有效率差异接近显著性边界（P=0.052），临床绝对风险降低率（Absolute Risk Reduction，ARR）达15.9%，1年总治愈率（70.0% vs 47.4%）及半年复发率（0.0% vs 15.8%）均显著优于西医组（P＜0.05）。激素使用时长缩短50%（P＜0.05），治疗后乳房满意度提升14.3%，SF-36总分提高14.0%，且与激素使用时长和乳房形态保留存在显著相关性（P＜0.01）。结论：“外科手术－激素治疗－中医药治疗”中西医结合分期论治通过降低复发率、减少激素依赖性和改善生活质量，显著提升了GLM的治疗效果，SF-36量表在综合疗效评估中具有重要价值。

  关键词： 肉芽肿性小叶性乳腺炎; 中西医结合治疗; 分期论治; 生活质量; SF-36量表

   

  Abstract: Objective: To investigate the clinical efficacy of integrated traditional Chinese and Western medicine staging treatment strategy for granulomatous lobular mastitis (GLM) at different stages and its impact on patients quality of life. Methods: A retrospective analysis of 78 GLM patients (June 2022-June 2024) compared an integrated treatment group (n=40, tailored herbal medicine with low-dose hormones/surgery) versus a Western medicine group (n=38, hormones/surgery). Outcomes included clinical efficacy (total effective rate, recurrence rate, hormone duration, breast appearance satisfaction) and 36-item Short Form Health Survey (SF-36). Results: No statistically significant differences were observed between the two groups in the 6-month total effective rate or 6-month total cure rate (P>0.05). The 1-year total effective rate in the integrated group approached borderline significance (P=0.052), with an Absolute Risk Reduction (ARR) of 15.9%. The integrated group demonstrated superior 1-year total cure rate (70.0% vs. 47.4%) and 6-month recurrence rate (0.0% vs 15.8%) compared to the Western group (all P<0.05). Hormone use duration was reduced by 50% (P<0.05), postoperative breast satisfaction scores improved by 14.3%, and SF-36 total scores increased by 14.0%, showing significant correlations with hormone duration and breast preservation (P<0.01). Conclusions: The surgery-hormone therapy-Traditional Chinese Medicine Treatment staging protocol significantly enhances GLM outcomes by reducing recurrence, decreasing hormonal dependency, and improving quality of life. SF-36 proves valuable for comprehensive efficacy evaluation.

  Key words: Granulomatous lobular mastitis; Integrated traditional Chinese-Western medicine; Staging therapy; Quality of life; SF-36 scale

  提交时间：2026-03-23

  版权声明：作者本人独立拥有该论文的版权，预印本系统仅拥有论文的永久保存权利。任何人未经允许不得重复使用。
• html

• 图表

• 谢怡昕, 曹心怡, 金珞瑶, 楼毅云. 抗磷脂综合征合并不孕患者人工授精失败后的中西医结合治疗经验浅析. 2026. doi: 10.12201/bmr.202603.00008

  陈豪特, 沈建武, 包烨华, 朱栎巧, 诸靖宇. 中西医结合治疗住院老年患者失眠症. 2024. doi: 10.12201/bmr.202407.00059

  杨玥, 张利英, 殷祎隆, 龚红霞, 寇炜. 中西医结合与思维导图在人体寄生虫学教学中的应用. 2026. doi: 10.12201/bmr.202602.00087

  黄天健, 陈佳英, 喻江婷, 周一鸣, 许雷来, 顾锡冬. 发酵乳杆菌 CECT5716 联合阳和汤治疗阴证非哺乳期乳腺炎临床观察. 2026. doi: 10.12201/bmr.202601.00023

  葛桑榆, 杨华娣, 李慧, 张晨, 毛佩瑜. 中药或中西药结合治疗子宫内膜异位症有效性及安全性的Meta分析. 2026. doi: 10.12201/bmr.202602.00053

  陈文会. 盆腔炎性疾病后遗症中西医发病机制及治疗研究进展. 2026. doi: 10.12201/bmr.202602.00059

  王亚楠, 王欢, 马莹, 田婧楠, 卢义. 免疫检查点抑制剂相关性甲状腺功能减退的中西医诊疗进展. 2025. doi: 10.12201/bmr.202505.00004

  刘星, 卓睿. 基于“气血水”理论辨治肉芽肿性乳腺炎. 2025. doi: 10.12201/bmr.202507.00041

  郭晴晴. 胃肠恶性肿瘤化疗后骨髓抑制中西医研究进展. 2025. doi: 10.12201/bmr.202506.00008

  蔡玉潇, 古英▲. 风湿性多肌痛的中西医治疗研究进展. 2025. doi: 10.12201/bmr.202506.00040

• 序号	提交日期	编号	操作
  1	2025-10-20	10.12201/bmr.202603.00103V1	下载

• 公开评论  匿名评论  仅发给作者 提交评论